nodes	percent_of_prediction	percent_of_DWPC	metapath
Quinine—CYP1A1—Clobetasol propionate—psoriasis	0.0717	0.0944	CbGbCtD
Quinine—CYP1A1—Methoxsalen—psoriasis	0.0377	0.0496	CbGbCtD
Quinine—CYP2C8—Tazarotene—psoriasis	0.0337	0.0444	CbGbCtD
Quinine—CYP3A5—Beclomethasone—psoriasis	0.0326	0.043	CbGbCtD
Quinine—CYP1A2—Clobetasol propionate—psoriasis	0.032	0.0422	CbGbCtD
Quinine—SLCO1A2—Prednisolone—psoriasis	0.0265	0.0349	CbGbCtD
Quinine—SLCO1A2—Hydrocortisone—psoriasis	0.0251	0.0331	CbGbCtD
Quinine—SLCO1A2—Prednisone—psoriasis	0.025	0.0329	CbGbCtD
Quinine—CYP1A1—Cholecalciferol—psoriasis	0.025	0.0329	CbGbCtD
Quinine—SLCO1A2—Cyclosporine—psoriasis	0.0237	0.0312	CbGbCtD
Quinine—CYP1A2—Methoxsalen—psoriasis	0.0168	0.0222	CbGbCtD
Quinine—SLCO1A2—Dexamethasone—psoriasis	0.0156	0.0206	CbGbCtD
Quinine—CYP2D6—Hydroxyurea—psoriasis	0.0152	0.02	CbGbCtD
Quinine—CYP2C8—Cholecalciferol—psoriasis	0.0144	0.019	CbGbCtD
Quinine—CYP3A7—Hydrocortisone—psoriasis	0.0139	0.0183	CbGbCtD
Quinine—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0139	0.0183	CbGbCtD
Quinine—CYP3A7—Cyclosporine—psoriasis	0.0131	0.0173	CbGbCtD
Quinine—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0131	0.0173	CbGbCtD
Quinine—CYP3A5—Mycophenolate mofetil—psoriasis	0.013	0.0171	CbGbCtD
Quinine—SLCO1A2—Methotrexate—psoriasis	0.0125	0.0165	CbGbCtD
Quinine—CYP2C8—Mycophenolate mofetil—psoriasis	0.0125	0.0164	CbGbCtD
Quinine—CYP2C19—Cholecalciferol—psoriasis	0.0121	0.0159	CbGbCtD
Quinine—CYP3A4—Calcitriol—psoriasis	0.0113	0.0149	CbGbCtD
Quinine—CYP1A1—Dexamethasone—psoriasis	0.0108	0.0142	CbGbCtD
Quinine—CYP3A5—Hydrocortisone—psoriasis	0.0104	0.0137	CbGbCtD
Quinine—CYP2C9—Cholecalciferol—psoriasis	0.01	0.0132	CbGbCtD
Quinine—CYP2C8—Hydrocortisone—psoriasis	0.01	0.0132	CbGbCtD
Quinine—CYP3A5—Cyclosporine—psoriasis	0.00984	0.013	CbGbCtD
Quinine—CYP2C8—Cyclosporine—psoriasis	0.00946	0.0125	CbGbCtD
Quinine—CYP2D6—Cholecalciferol—psoriasis	0.00919	0.0121	CbGbCtD
Quinine—CYP3A4—Methoxsalen—psoriasis	0.00882	0.0116	CbGbCtD
Quinine—CYP3A7—Dexamethasone—psoriasis	0.00864	0.0114	CbGbCtD
Quinine—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00864	0.0114	CbGbCtD
Quinine—ABCB1—Mycophenolate mofetil—psoriasis	0.00845	0.0111	CbGbCtD
Quinine—CYP2C19—Prednisone—psoriasis	0.00837	0.011	CbGbCtD
Quinine—CYP2E1—Dexamethasone—psoriasis	0.00834	0.011	CbGbCtD
Quinine—CYP2C19—Cyclosporine—psoriasis	0.00794	0.0105	CbGbCtD
Quinine—ABCB1—Betamethasone—psoriasis	0.00725	0.00955	CbGbCtD
Quinine—ABCB1—Prednisolone—psoriasis	0.00715	0.00942	CbGbCtD
Quinine—ABCB1—Hydrocortisone—psoriasis	0.00678	0.00893	CbGbCtD
Quinine—ABCB1—Prednisone—psoriasis	0.00676	0.0089	CbGbCtD
Quinine—CYP2C9—Cyclosporine—psoriasis	0.0066	0.00869	CbGbCtD
Quinine—CYP3A5—Dexamethasone—psoriasis	0.00648	0.00854	CbGbCtD
Quinine—ABCB1—Cyclosporine—psoriasis	0.00641	0.00844	CbGbCtD
Quinine—CYP2C8—Dexamethasone—psoriasis	0.00623	0.00821	CbGbCtD
Quinine—CYP2D6—Cyclosporine—psoriasis	0.00604	0.00795	CbGbCtD
Quinine—CYP3A4—Cholecalciferol—psoriasis	0.00584	0.00769	CbGbCtD
Quinine—CYP2C19—Dexamethasone—psoriasis	0.00523	0.00688	CbGbCtD
Quinine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00506	0.00667	CbGbCtD
Quinine—CYP3A4—Triamcinolone—psoriasis	0.00506	0.00667	CbGbCtD
Quinine—CYP2C9—Dexamethasone—psoriasis	0.00435	0.00572	CbGbCtD
Quinine—CYP3A4—Betamethasone—psoriasis	0.00434	0.00572	CbGbCtD
Quinine—CYP3A4—Prednisolone—psoriasis	0.00429	0.00565	CbGbCtD
Quinine—ABCB1—Dexamethasone—psoriasis	0.00422	0.00555	CbGbCtD
Quinine—CYP3A4—Hydrocortisone—psoriasis	0.00406	0.00535	CbGbCtD
Quinine—CYP3A4—Prednisone—psoriasis	0.00405	0.00533	CbGbCtD
Quinine—CYP2D6—Dexamethasone—psoriasis	0.00397	0.00523	CbGbCtD
Quinine—CYP3A4—Cyclosporine—psoriasis	0.00384	0.00505	CbGbCtD
Quinine—ABCB1—Methotrexate—psoriasis	0.00339	0.00446	CbGbCtD
Quinine—CYP3A4—Dexamethasone—psoriasis	0.00253	0.00333	CbGbCtD
Quinine—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000135	0.0034	CbGpPWpGaD
Quinine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000135	0.00339	CbGpPWpGaD
Quinine—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000133	0.00335	CbGpPWpGaD
Quinine—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.00013	0.00326	CbGpPWpGaD
Quinine—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.000127	0.0032	CbGpPWpGaD
Quinine—SLC22A5—SLC-mediated transmembrane transport—CP—psoriasis	0.000126	0.00317	CbGpPWpGaD
Quinine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000126	0.00317	CbGpPWpGaD
Quinine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000125	0.00316	CbGpPWpGaD
Quinine—GP9—Hemostasis—NOS2—psoriasis	0.000123	0.00311	CbGpPWpGaD
Quinine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000121	0.00304	CbGpPWpGaD
Quinine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000119	0.00299	CbGpPWpGaD
Quinine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000117	0.00295	CbGpPWpGaD
Quinine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000117	0.00294	CbGpPWpGaD
Quinine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000116	0.00293	CbGpPWpGaD
Quinine—CHRM2—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000114	0.00287	CbGpPWpGaD
Quinine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000111	0.00279	CbGpPWpGaD
Quinine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.00011	0.00277	CbGpPWpGaD
Quinine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000109	0.00275	CbGpPWpGaD
Quinine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000108	0.00273	CbGpPWpGaD
Quinine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000107	0.00271	CbGpPWpGaD
Quinine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000107	0.00269	CbGpPWpGaD
Quinine—Nausea—Hydroxyurea—psoriasis	0.000106	0.000527	CcSEcCtD
Quinine—KCNH2—SIDS Susceptibility Pathways—IL10—psoriasis	0.000106	0.00267	CbGpPWpGaD
Quinine—Pruritus—Mycophenolic acid—psoriasis	0.000106	0.000526	CcSEcCtD
Quinine—Shock—Hydrocortisone—psoriasis	0.000106	0.000525	CcSEcCtD
Quinine—Myalgia—Triamcinolone—psoriasis	0.000105	0.000525	CcSEcCtD
Quinine—Nervous system disorder—Hydrocortisone—psoriasis	0.000105	0.000524	CcSEcCtD
Quinine—Eye disorder—Prednisone—psoriasis	0.000105	0.000523	CcSEcCtD
Quinine—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000105	0.000523	CcSEcCtD
Quinine—Decreased appetite—Cyclosporine—psoriasis	0.000105	0.000522	CcSEcCtD
Quinine—Tachycardia—Hydrocortisone—psoriasis	0.000105	0.000521	CcSEcCtD
Quinine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000105	0.00264	CbGpPWpGaD
Quinine—Flushing—Prednisone—psoriasis	0.000104	0.000519	CcSEcCtD
Quinine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000104	0.000519	CcSEcCtD
Quinine—Skin disorder—Hydrocortisone—psoriasis	0.000104	0.000519	CcSEcCtD
Quinine—Hyperhidrosis—Hydrocortisone—psoriasis	0.000104	0.000516	CcSEcCtD
Quinine—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000104	0.000516	CcSEcCtD
Quinine—Renal failure—Methotrexate—psoriasis	0.000103	0.000512	CcSEcCtD
Quinine—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	0.000103	0.00259	CbGpPWpGaD
Quinine—Angioedema—Betamethasone—psoriasis	0.000103	0.000511	CcSEcCtD
Quinine—Angioedema—Dexamethasone—psoriasis	0.000103	0.000511	CcSEcCtD
Quinine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000102	0.00051	CcSEcCtD
Quinine—Anorexia—Hydrocortisone—psoriasis	0.000102	0.000509	CcSEcCtD
Quinine—Diarrhoea—Mycophenolic acid—psoriasis	0.000102	0.000508	CcSEcCtD
Quinine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000102	0.000506	CcSEcCtD
Quinine—Immune system disorder—Prednisone—psoriasis	0.000102	0.000505	CcSEcCtD
Quinine—Oedema—Triamcinolone—psoriasis	0.000101	0.000503	CcSEcCtD
Quinine—SLCO1A2—SLC-mediated transmembrane transport—CP—psoriasis	0.000101	0.00255	CbGpPWpGaD
Quinine—Vertigo—Dexamethasone—psoriasis	0.000101	0.000502	CcSEcCtD
Quinine—Vertigo—Betamethasone—psoriasis	0.000101	0.000502	CcSEcCtD
Quinine—Syncope—Dexamethasone—psoriasis	0.000101	0.000501	CcSEcCtD
Quinine—Syncope—Betamethasone—psoriasis	0.000101	0.000501	CcSEcCtD
Quinine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000101	0.00254	CbGpPWpGaD
Quinine—Sweating—Methotrexate—psoriasis	0.0001	0.000499	CcSEcCtD
Quinine—Hypotension—Hydrocortisone—psoriasis	0.0001	0.000499	CcSEcCtD
Quinine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.0001	0.00252	CbGpPWpGaD
Quinine—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.0001	0.00252	CbGpPWpGaD
Quinine—Feeling abnormal—Cyclosporine—psoriasis	9.95e-05	0.000495	CcSEcCtD
Quinine—Shock—Triamcinolone—psoriasis	9.94e-05	0.000495	CcSEcCtD
Quinine—ABCB1—Allograft Rejection—IL13—psoriasis	9.94e-05	0.0025	CbGpPWpGaD
Quinine—Gastrointestinal pain—Cyclosporine—psoriasis	9.88e-05	0.000491	CcSEcCtD
Quinine—Loss of consciousness—Betamethasone—psoriasis	9.88e-05	0.000491	CcSEcCtD
Quinine—Loss of consciousness—Dexamethasone—psoriasis	9.88e-05	0.000491	CcSEcCtD
Quinine—Dizziness—Mycophenolic acid—psoriasis	9.87e-05	0.000491	CcSEcCtD
Quinine—Tachycardia—Triamcinolone—psoriasis	9.86e-05	0.000491	CcSEcCtD
Quinine—Mental disorder—Prednisone—psoriasis	9.85e-05	0.00049	CcSEcCtD
Quinine—Erythema—Prednisone—psoriasis	9.79e-05	0.000487	CcSEcCtD
Quinine—Malnutrition—Prednisone—psoriasis	9.79e-05	0.000487	CcSEcCtD
Quinine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	9.78e-05	0.000487	CcSEcCtD
Quinine—Hyperhidrosis—Triamcinolone—psoriasis	9.77e-05	0.000486	CcSEcCtD
Quinine—Agranulocytosis—Methotrexate—psoriasis	9.77e-05	0.000486	CcSEcCtD
Quinine—Convulsion—Dexamethasone—psoriasis	9.74e-05	0.000484	CcSEcCtD
Quinine—Convulsion—Betamethasone—psoriasis	9.74e-05	0.000484	CcSEcCtD
Quinine—Feeling abnormal—Mycophenolate mofetil—psoriasis	9.71e-05	0.000483	CcSEcCtD
Quinine—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—psoriasis	9.65e-05	0.00243	CbGpPWpGaD
Quinine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	9.63e-05	0.000479	CcSEcCtD
Quinine—Urticaria—Cyclosporine—psoriasis	9.59e-05	0.000477	CcSEcCtD
Quinine—CHRM2—GPCR ligand binding—HCAR2—psoriasis	9.57e-05	0.00241	CbGpPWpGaD
Quinine—Myalgia—Betamethasone—psoriasis	9.57e-05	0.000476	CcSEcCtD
Quinine—Myalgia—Dexamethasone—psoriasis	9.57e-05	0.000476	CcSEcCtD
Quinine—Abdominal pain—Cyclosporine—psoriasis	9.55e-05	0.000475	CcSEcCtD
Quinine—Body temperature increased—Cyclosporine—psoriasis	9.55e-05	0.000475	CcSEcCtD
Quinine—Vomiting—Mycophenolic acid—psoriasis	9.49e-05	0.000472	CcSEcCtD
Quinine—Haemoglobin—Methotrexate—psoriasis	9.44e-05	0.00047	CcSEcCtD
Quinine—Rash—Mycophenolic acid—psoriasis	9.41e-05	0.000468	CcSEcCtD
Quinine—Dermatitis—Mycophenolic acid—psoriasis	9.4e-05	0.000468	CcSEcCtD
Quinine—Hepatitis—Methotrexate—psoriasis	9.39e-05	0.000467	CcSEcCtD
Quinine—Haemorrhage—Methotrexate—psoriasis	9.39e-05	0.000467	CcSEcCtD
Quinine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	9.39e-05	0.00237	CbGpPWpGaD
Quinine—Urticaria—Mycophenolate mofetil—psoriasis	9.36e-05	0.000466	CcSEcCtD
Quinine—Headache—Mycophenolic acid—psoriasis	9.35e-05	0.000465	CcSEcCtD
Quinine—Decreased appetite—Hydrocortisone—psoriasis	9.33e-05	0.000464	CcSEcCtD
Quinine—Abdominal pain—Mycophenolate mofetil—psoriasis	9.31e-05	0.000463	CcSEcCtD
Quinine—Body temperature increased—Mycophenolate mofetil—psoriasis	9.31e-05	0.000463	CcSEcCtD
Quinine—Urinary tract disorder—Methotrexate—psoriasis	9.28e-05	0.000462	CcSEcCtD
Quinine—Gastrointestinal disorder—Hydrocortisone—psoriasis	9.27e-05	0.000461	CcSEcCtD
Quinine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	9.26e-05	0.00233	CbGpPWpGaD
Quinine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	9.24e-05	0.00233	CbGpPWpGaD
Quinine—Vision blurred—Prednisone—psoriasis	9.22e-05	0.000459	CcSEcCtD
Quinine—Urethral disorder—Methotrexate—psoriasis	9.21e-05	0.000458	CcSEcCtD
Quinine—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.21e-05	0.000458	CcSEcCtD
Quinine—Oedema—Betamethasone—psoriasis	9.17e-05	0.000456	CcSEcCtD
Quinine—Oedema—Dexamethasone—psoriasis	9.17e-05	0.000456	CcSEcCtD
Quinine—ABCB1—Allograft Rejection—IL17A—psoriasis	9.15e-05	0.0023	CbGpPWpGaD
Quinine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	9.1e-05	0.00229	CbGpPWpGaD
Quinine—Feeling abnormal—Prednisolone—psoriasis	9.06e-05	0.000451	CcSEcCtD
Quinine—Visual impairment—Methotrexate—psoriasis	9.05e-05	0.000451	CcSEcCtD
Quinine—Shock—Betamethasone—psoriasis	9.02e-05	0.000449	CcSEcCtD
Quinine—Shock—Dexamethasone—psoriasis	9.02e-05	0.000449	CcSEcCtD
Quinine—Dyspnoea—Triamcinolone—psoriasis	9.01e-05	0.000448	CcSEcCtD
Quinine—CHRM2—SIDS Susceptibility Pathways—IL13—psoriasis	9e-05	0.00227	CbGpPWpGaD
Quinine—Nervous system disorder—Dexamethasone—psoriasis	8.99e-05	0.000448	CcSEcCtD
Quinine—Nervous system disorder—Betamethasone—psoriasis	8.99e-05	0.000448	CcSEcCtD
Quinine—Agitation—Prednisone—psoriasis	8.99e-05	0.000447	CcSEcCtD
Quinine—Thrombocytopenia—Dexamethasone—psoriasis	8.98e-05	0.000447	CcSEcCtD
Quinine—Thrombocytopenia—Betamethasone—psoriasis	8.98e-05	0.000447	CcSEcCtD
Quinine—Tachycardia—Dexamethasone—psoriasis	8.95e-05	0.000445	CcSEcCtD
Quinine—Tachycardia—Betamethasone—psoriasis	8.95e-05	0.000445	CcSEcCtD
Quinine—Angioedema—Prednisone—psoriasis	8.94e-05	0.000445	CcSEcCtD
Quinine—Hypersensitivity—Cyclosporine—psoriasis	8.9e-05	0.000443	CcSEcCtD
Quinine—Erythema multiforme—Methotrexate—psoriasis	8.88e-05	0.000442	CcSEcCtD
Quinine—Nausea—Mycophenolic acid—psoriasis	8.87e-05	0.000441	CcSEcCtD
Quinine—Hyperhidrosis—Dexamethasone—psoriasis	8.87e-05	0.000441	CcSEcCtD
Quinine—Hyperhidrosis—Betamethasone—psoriasis	8.87e-05	0.000441	CcSEcCtD
Quinine—Feeling abnormal—Hydrocortisone—psoriasis	8.85e-05	0.00044	CcSEcCtD
Quinine—Vertigo—Prednisone—psoriasis	8.79e-05	0.000437	CcSEcCtD
Quinine—Eye disorder—Methotrexate—psoriasis	8.78e-05	0.000437	CcSEcCtD
Quinine—Gastrointestinal pain—Hydrocortisone—psoriasis	8.78e-05	0.000437	CcSEcCtD
Quinine—Syncope—Prednisone—psoriasis	8.78e-05	0.000437	CcSEcCtD
Quinine—Tinnitus—Methotrexate—psoriasis	8.76e-05	0.000436	CcSEcCtD
Quinine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.75e-05	0.0022	CbGpPWpGaD
Quinine—Anorexia—Dexamethasone—psoriasis	8.74e-05	0.000435	CcSEcCtD
Quinine—Anorexia—Betamethasone—psoriasis	8.74e-05	0.000435	CcSEcCtD
Quinine—Urticaria—Prednisolone—psoriasis	8.73e-05	0.000434	CcSEcCtD
Quinine—Cardiac disorder—Methotrexate—psoriasis	8.72e-05	0.000434	CcSEcCtD
Quinine—Hypersensitivity—Mycophenolate mofetil—psoriasis	8.68e-05	0.000432	CcSEcCtD
Quinine—Asthenia—Cyclosporine—psoriasis	8.67e-05	0.000431	CcSEcCtD
Quinine—Loss of consciousness—Prednisone—psoriasis	8.6e-05	0.000428	CcSEcCtD
Quinine—Hypotension—Dexamethasone—psoriasis	8.57e-05	0.000426	CcSEcCtD
Quinine—Hypotension—Betamethasone—psoriasis	8.57e-05	0.000426	CcSEcCtD
Quinine—Pruritus—Cyclosporine—psoriasis	8.54e-05	0.000425	CcSEcCtD
Quinine—Urticaria—Hydrocortisone—psoriasis	8.53e-05	0.000424	CcSEcCtD
Quinine—SLC22A4—Transmembrane transport of small molecules—CP—psoriasis	8.51e-05	0.00214	CbGpPWpGaD
Quinine—ABCB1—Allograft Rejection—IL12B—psoriasis	8.5e-05	0.00214	CbGpPWpGaD
Quinine—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	8.49e-05	0.00214	CbGpPWpGaD
Quinine—Immune system disorder—Methotrexate—psoriasis	8.49e-05	0.000422	CcSEcCtD
Quinine—Abdominal pain—Hydrocortisone—psoriasis	8.49e-05	0.000422	CcSEcCtD
Quinine—Body temperature increased—Hydrocortisone—psoriasis	8.49e-05	0.000422	CcSEcCtD
Quinine—Convulsion—Prednisone—psoriasis	8.48e-05	0.000422	CcSEcCtD
Quinine—Mediastinal disorder—Methotrexate—psoriasis	8.47e-05	0.000421	CcSEcCtD
Quinine—Asthenia—Mycophenolate mofetil—psoriasis	8.45e-05	0.000421	CcSEcCtD
Quinine—Chills—Methotrexate—psoriasis	8.43e-05	0.000419	CcSEcCtD
Quinine—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.35e-05	0.000416	CcSEcCtD
Quinine—Musculoskeletal discomfort—Betamethasone—psoriasis	8.35e-05	0.000416	CcSEcCtD
Quinine—Pruritus—Mycophenolate mofetil—psoriasis	8.34e-05	0.000415	CcSEcCtD
Quinine—Myalgia—Prednisone—psoriasis	8.33e-05	0.000415	CcSEcCtD
Quinine—Feeling abnormal—Triamcinolone—psoriasis	8.33e-05	0.000414	CcSEcCtD
Quinine—ABCB1—Allograft Rejection—HLA-E—psoriasis	8.3e-05	0.00209	CbGpPWpGaD
Quinine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	8.27e-05	0.000412	CcSEcCtD
Quinine—CYP1A1—Oxidative Stress—NFKB1—psoriasis	8.26e-05	0.00208	CbGpPWpGaD
Quinine—Diarrhoea—Cyclosporine—psoriasis	8.26e-05	0.000411	CcSEcCtD
Quinine—Mental disorder—Methotrexate—psoriasis	8.23e-05	0.00041	CcSEcCtD
Quinine—CHRM2—G alpha (i) signalling events—CCL20—psoriasis	8.21e-05	0.00207	CbGpPWpGaD
Quinine—Malnutrition—Methotrexate—psoriasis	8.18e-05	0.000407	CcSEcCtD
Quinine—Erythema—Methotrexate—psoriasis	8.18e-05	0.000407	CcSEcCtD
Quinine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.17e-05	0.00206	CbGpPWpGaD
Quinine—SLC22A4—Transmembrane transport of small molecules—CARM1—psoriasis	8.12e-05	0.00205	CbGpPWpGaD
Quinine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	8.1e-05	0.00204	CbGpPWpGaD
Quinine—Hypersensitivity—Prednisolone—psoriasis	8.1e-05	0.000403	CcSEcCtD
Quinine—Diarrhoea—Mycophenolate mofetil—psoriasis	8.06e-05	0.000401	CcSEcCtD
Quinine—Urticaria—Triamcinolone—psoriasis	8.03e-05	0.0004	CcSEcCtD
Quinine—Body temperature increased—Triamcinolone—psoriasis	7.99e-05	0.000398	CcSEcCtD
Quinine—Dizziness—Cyclosporine—psoriasis	7.99e-05	0.000397	CcSEcCtD
Quinine—Oedema—Prednisone—psoriasis	7.99e-05	0.000397	CcSEcCtD
Quinine—Decreased appetite—Dexamethasone—psoriasis	7.97e-05	0.000397	CcSEcCtD
Quinine—Decreased appetite—Betamethasone—psoriasis	7.97e-05	0.000397	CcSEcCtD
Quinine—SLC22A2—SLC-mediated transmembrane transport—CP—psoriasis	7.92e-05	0.002	CbGpPWpGaD
Quinine—Gastrointestinal disorder—Dexamethasone—psoriasis	7.92e-05	0.000394	CcSEcCtD
Quinine—Gastrointestinal disorder—Betamethasone—psoriasis	7.92e-05	0.000394	CcSEcCtD
Quinine—Hypersensitivity—Hydrocortisone—psoriasis	7.91e-05	0.000394	CcSEcCtD
Quinine—Shock—Prednisone—psoriasis	7.86e-05	0.000391	CcSEcCtD
Quinine—Nervous system disorder—Prednisone—psoriasis	7.83e-05	0.00039	CcSEcCtD
Quinine—Tachycardia—Prednisone—psoriasis	7.79e-05	0.000388	CcSEcCtD
Quinine—Dizziness—Mycophenolate mofetil—psoriasis	7.79e-05	0.000388	CcSEcCtD
Quinine—Skin disorder—Prednisone—psoriasis	7.76e-05	0.000386	CcSEcCtD
Quinine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.73e-05	0.00195	CbGpPWpGaD
Quinine—Hyperhidrosis—Prednisone—psoriasis	7.72e-05	0.000384	CcSEcCtD
Quinine—Vision blurred—Methotrexate—psoriasis	7.71e-05	0.000384	CcSEcCtD
Quinine—Asthenia—Hydrocortisone—psoriasis	7.7e-05	0.000383	CcSEcCtD
Quinine—Vomiting—Cyclosporine—psoriasis	7.68e-05	0.000382	CcSEcCtD
Quinine—Rash—Cyclosporine—psoriasis	7.62e-05	0.000379	CcSEcCtD
Quinine—Anorexia—Prednisone—psoriasis	7.61e-05	0.000379	CcSEcCtD
Quinine—Dermatitis—Cyclosporine—psoriasis	7.61e-05	0.000379	CcSEcCtD
Quinine—Pruritus—Hydrocortisone—psoriasis	7.59e-05	0.000378	CcSEcCtD
Quinine—Headache—Cyclosporine—psoriasis	7.57e-05	0.000377	CcSEcCtD
Quinine—Feeling abnormal—Dexamethasone—psoriasis	7.56e-05	0.000376	CcSEcCtD
Quinine—Feeling abnormal—Betamethasone—psoriasis	7.56e-05	0.000376	CcSEcCtD
Quinine—Gastrointestinal pain—Betamethasone—psoriasis	7.5e-05	0.000373	CcSEcCtD
Quinine—Gastrointestinal pain—Dexamethasone—psoriasis	7.5e-05	0.000373	CcSEcCtD
Quinine—Vomiting—Mycophenolate mofetil—psoriasis	7.49e-05	0.000373	CcSEcCtD
Quinine—Hypersensitivity—Triamcinolone—psoriasis	7.45e-05	0.000371	CcSEcCtD
Quinine—Rash—Mycophenolate mofetil—psoriasis	7.43e-05	0.00037	CcSEcCtD
Quinine—Dermatitis—Mycophenolate mofetil—psoriasis	7.42e-05	0.000369	CcSEcCtD
Quinine—SLC22A1—SLC-mediated transmembrane transport—CP—psoriasis	7.38e-05	0.00186	CbGpPWpGaD
Quinine—Headache—Mycophenolate mofetil—psoriasis	7.38e-05	0.000367	CcSEcCtD
Quinine—Vertigo—Methotrexate—psoriasis	7.35e-05	0.000366	CcSEcCtD
Quinine—Diarrhoea—Hydrocortisone—psoriasis	7.34e-05	0.000365	CcSEcCtD
Quinine—Leukopenia—Methotrexate—psoriasis	7.32e-05	0.000364	CcSEcCtD
Quinine—Urticaria—Betamethasone—psoriasis	7.29e-05	0.000363	CcSEcCtD
Quinine—Urticaria—Dexamethasone—psoriasis	7.29e-05	0.000363	CcSEcCtD
Quinine—Musculoskeletal discomfort—Prednisone—psoriasis	7.28e-05	0.000362	CcSEcCtD
Quinine—Dizziness—Prednisolone—psoriasis	7.27e-05	0.000362	CcSEcCtD
Quinine—Asthenia—Triamcinolone—psoriasis	7.25e-05	0.000361	CcSEcCtD
Quinine—Body temperature increased—Betamethasone—psoriasis	7.25e-05	0.000361	CcSEcCtD
Quinine—Abdominal pain—Dexamethasone—psoriasis	7.25e-05	0.000361	CcSEcCtD
Quinine—Abdominal pain—Betamethasone—psoriasis	7.25e-05	0.000361	CcSEcCtD
Quinine—Body temperature increased—Dexamethasone—psoriasis	7.25e-05	0.000361	CcSEcCtD
Quinine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	7.25e-05	0.00183	CbGpPWpGaD
Quinine—Nausea—Cyclosporine—psoriasis	7.17e-05	0.000357	CcSEcCtD
Quinine—Pruritus—Triamcinolone—psoriasis	7.15e-05	0.000356	CcSEcCtD
Quinine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	7.15e-05	0.0018	CbGpPWpGaD
Quinine—GP9—Hemostasis—VEGFA—psoriasis	7.15e-05	0.0018	CbGpPWpGaD
Quinine—Dizziness—Hydrocortisone—psoriasis	7.1e-05	0.000353	CcSEcCtD
Quinine—Convulsion—Methotrexate—psoriasis	7.09e-05	0.000353	CcSEcCtD
Quinine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	7.06e-05	0.00178	CbGpPWpGaD
Quinine—Nausea—Mycophenolate mofetil—psoriasis	7e-05	0.000348	CcSEcCtD
Quinine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.98e-05	0.00176	CbGpPWpGaD
Quinine—Chest pain—Methotrexate—psoriasis	6.96e-05	0.000346	CcSEcCtD
Quinine—Myalgia—Methotrexate—psoriasis	6.96e-05	0.000346	CcSEcCtD
Quinine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	6.95e-05	0.00175	CbGpPWpGaD
Quinine—Decreased appetite—Prednisone—psoriasis	6.94e-05	0.000345	CcSEcCtD
Quinine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	6.93e-05	0.00175	CbGpPWpGaD
Quinine—Rash—Prednisolone—psoriasis	6.93e-05	0.000345	CcSEcCtD
Quinine—Dermatitis—Prednisolone—psoriasis	6.92e-05	0.000345	CcSEcCtD
Quinine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	6.91e-05	0.000344	CcSEcCtD
Quinine—Headache—Prednisolone—psoriasis	6.88e-05	0.000343	CcSEcCtD
Quinine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	6.87e-05	0.00173	CbGpPWpGaD
Quinine—Vomiting—Hydrocortisone—psoriasis	6.82e-05	0.00034	CcSEcCtD
Quinine—Rash—Hydrocortisone—psoriasis	6.77e-05	0.000337	CcSEcCtD
Quinine—Dermatitis—Hydrocortisone—psoriasis	6.76e-05	0.000336	CcSEcCtD
Quinine—Confusional state—Methotrexate—psoriasis	6.73e-05	0.000335	CcSEcCtD
Quinine—Headache—Hydrocortisone—psoriasis	6.72e-05	0.000335	CcSEcCtD
Quinine—Dizziness—Triamcinolone—psoriasis	6.68e-05	0.000333	CcSEcCtD
Quinine—Feeling abnormal—Prednisone—psoriasis	6.58e-05	0.000327	CcSEcCtD
Quinine—Asthenia—Dexamethasone—psoriasis	6.58e-05	0.000327	CcSEcCtD
Quinine—Asthenia—Betamethasone—psoriasis	6.58e-05	0.000327	CcSEcCtD
Quinine—Nervous system disorder—Methotrexate—psoriasis	6.55e-05	0.000326	CcSEcCtD
Quinine—Thrombocytopenia—Methotrexate—psoriasis	6.53e-05	0.000325	CcSEcCtD
Quinine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	6.53e-05	0.00165	CbGpPWpGaD
Quinine—Gastrointestinal pain—Prednisone—psoriasis	6.53e-05	0.000325	CcSEcCtD
Quinine—Nausea—Prednisolone—psoriasis	6.53e-05	0.000325	CcSEcCtD
Quinine—Pruritus—Betamethasone—psoriasis	6.49e-05	0.000323	CcSEcCtD
Quinine—Pruritus—Dexamethasone—psoriasis	6.49e-05	0.000323	CcSEcCtD
Quinine—Skin disorder—Methotrexate—psoriasis	6.48e-05	0.000323	CcSEcCtD
Quinine—Hyperhidrosis—Methotrexate—psoriasis	6.45e-05	0.000321	CcSEcCtD
Quinine—Vomiting—Triamcinolone—psoriasis	6.43e-05	0.00032	CcSEcCtD
Quinine—SLC22A5—Transmembrane transport of small molecules—CP—psoriasis	6.4e-05	0.00161	CbGpPWpGaD
Quinine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	6.39e-05	0.00161	CbGpPWpGaD
Quinine—Nausea—Hydrocortisone—psoriasis	6.38e-05	0.000317	CcSEcCtD
Quinine—Rash—Triamcinolone—psoriasis	6.37e-05	0.000317	CcSEcCtD
Quinine—Dermatitis—Triamcinolone—psoriasis	6.37e-05	0.000317	CcSEcCtD
Quinine—Anorexia—Methotrexate—psoriasis	6.36e-05	0.000317	CcSEcCtD
Quinine—Urticaria—Prednisone—psoriasis	6.34e-05	0.000316	CcSEcCtD
Quinine—Headache—Triamcinolone—psoriasis	6.33e-05	0.000315	CcSEcCtD
Quinine—Abdominal pain—Prednisone—psoriasis	6.31e-05	0.000314	CcSEcCtD
Quinine—Body temperature increased—Prednisone—psoriasis	6.31e-05	0.000314	CcSEcCtD
Quinine—Diarrhoea—Betamethasone—psoriasis	6.27e-05	0.000312	CcSEcCtD
Quinine—Diarrhoea—Dexamethasone—psoriasis	6.27e-05	0.000312	CcSEcCtD
Quinine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.25e-05	0.00158	CbGpPWpGaD
Quinine—Hypotension—Methotrexate—psoriasis	6.24e-05	0.00031	CcSEcCtD
Quinine—ABCB1—Allograft Rejection—IL10—psoriasis	6.22e-05	0.00157	CbGpPWpGaD
Quinine—SLC22A5—Transmembrane transport of small molecules—CARM1—psoriasis	6.1e-05	0.00154	CbGpPWpGaD
Quinine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	6.1e-05	0.00154	CbGpPWpGaD
Quinine—Musculoskeletal discomfort—Methotrexate—psoriasis	6.08e-05	0.000303	CcSEcCtD
Quinine—Dizziness—Betamethasone—psoriasis	6.06e-05	0.000302	CcSEcCtD
Quinine—Dizziness—Dexamethasone—psoriasis	6.06e-05	0.000302	CcSEcCtD
Quinine—ABCB1—Allograft Rejection—IL4—psoriasis	6.05e-05	0.00152	CbGpPWpGaD
Quinine—Nausea—Triamcinolone—psoriasis	6e-05	0.000299	CcSEcCtD
Quinine—Dyspnoea—Methotrexate—psoriasis	5.95e-05	0.000296	CcSEcCtD
Quinine—ABCB1—Allograft Rejection—HLA-B—psoriasis	5.91e-05	0.00149	CbGpPWpGaD
Quinine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	5.91e-05	0.00149	CbGpPWpGaD
Quinine—Hypersensitivity—Prednisone—psoriasis	5.88e-05	0.000293	CcSEcCtD
Quinine—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.87e-05	0.00148	CbGpPWpGaD
Quinine—Vomiting—Betamethasone—psoriasis	5.83e-05	0.00029	CcSEcCtD
Quinine—Vomiting—Dexamethasone—psoriasis	5.83e-05	0.00029	CcSEcCtD
Quinine—Decreased appetite—Methotrexate—psoriasis	5.8e-05	0.000289	CcSEcCtD
Quinine—KCNH2—SIDS Susceptibility Pathways—CXCL8—psoriasis	5.79e-05	0.00146	CbGpPWpGaD
Quinine—Rash—Betamethasone—psoriasis	5.78e-05	0.000288	CcSEcCtD
Quinine—Rash—Dexamethasone—psoriasis	5.78e-05	0.000288	CcSEcCtD
Quinine—Dermatitis—Dexamethasone—psoriasis	5.78e-05	0.000287	CcSEcCtD
Quinine—Dermatitis—Betamethasone—psoriasis	5.78e-05	0.000287	CcSEcCtD
Quinine—Gastrointestinal disorder—Methotrexate—psoriasis	5.76e-05	0.000287	CcSEcCtD
Quinine—Headache—Dexamethasone—psoriasis	5.74e-05	0.000286	CcSEcCtD
Quinine—Headache—Betamethasone—psoriasis	5.74e-05	0.000286	CcSEcCtD
Quinine—Asthenia—Prednisone—psoriasis	5.73e-05	0.000285	CcSEcCtD
Quinine—Pruritus—Prednisone—psoriasis	5.65e-05	0.000281	CcSEcCtD
Quinine—CHRM2—SIDS Susceptibility Pathways—IL10—psoriasis	5.63e-05	0.00142	CbGpPWpGaD
Quinine—SLCO1A2—Metabolism—NDUFA5—psoriasis	5.53e-05	0.00139	CbGpPWpGaD
Quinine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	5.5e-05	0.00139	CbGpPWpGaD
Quinine—Feeling abnormal—Methotrexate—psoriasis	5.5e-05	0.000274	CcSEcCtD
Quinine—ABCB1—Allograft Rejection—HLA-A—psoriasis	5.48e-05	0.00138	CbGpPWpGaD
Quinine—Diarrhoea—Prednisone—psoriasis	5.46e-05	0.000272	CcSEcCtD
Quinine—Gastrointestinal pain—Methotrexate—psoriasis	5.46e-05	0.000272	CcSEcCtD
Quinine—Nausea—Betamethasone—psoriasis	5.45e-05	0.000271	CcSEcCtD
Quinine—Nausea—Dexamethasone—psoriasis	5.45e-05	0.000271	CcSEcCtD
Quinine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	5.41e-05	0.00136	CbGpPWpGaD
Quinine—CHRM2—GPCR downstream signaling—HCAR2—psoriasis	5.41e-05	0.00136	CbGpPWpGaD
Quinine—GP9—Hemostasis—TP53—psoriasis	5.4e-05	0.00136	CbGpPWpGaD
Quinine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.39e-05	0.00136	CbGpPWpGaD
Quinine—KCNH2—SIDS Susceptibility Pathways—JUN—psoriasis	5.38e-05	0.00136	CbGpPWpGaD
Quinine—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	5.33e-05	0.00134	CbGpPWpGaD
Quinine—Urticaria—Methotrexate—psoriasis	5.3e-05	0.000264	CcSEcCtD
Quinine—Dizziness—Prednisone—psoriasis	5.28e-05	0.000263	CcSEcCtD
Quinine—Abdominal pain—Methotrexate—psoriasis	5.28e-05	0.000263	CcSEcCtD
Quinine—Body temperature increased—Methotrexate—psoriasis	5.28e-05	0.000263	CcSEcCtD
Quinine—KCNH2—SIDS Susceptibility Pathways—NFKB1—psoriasis	5.18e-05	0.0013	CbGpPWpGaD
Quinine—SLCO1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.15e-05	0.0013	CbGpPWpGaD
Quinine—SLCO1A2—Transmembrane transport of small molecules—CP—psoriasis	5.14e-05	0.00129	CbGpPWpGaD
Quinine—Vomiting—Prednisone—psoriasis	5.08e-05	0.000253	CcSEcCtD
Quinine—Rash—Prednisone—psoriasis	5.04e-05	0.000251	CcSEcCtD
Quinine—Dermatitis—Prednisone—psoriasis	5.03e-05	0.00025	CcSEcCtD
Quinine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	5.01e-05	0.00126	CbGpPWpGaD
Quinine—Headache—Prednisone—psoriasis	5e-05	0.000249	CcSEcCtD
Quinine—CHRM2—GPCR ligand binding—CCL20—psoriasis	4.97e-05	0.00125	CbGpPWpGaD
Quinine—Hypersensitivity—Methotrexate—psoriasis	4.92e-05	0.000245	CcSEcCtD
Quinine—CHRM2—Signaling by GPCR—HCAR2—psoriasis	4.91e-05	0.00124	CbGpPWpGaD
Quinine—SLCO1A2—Transmembrane transport of small molecules—CARM1—psoriasis	4.9e-05	0.00123	CbGpPWpGaD
Quinine—Asthenia—Methotrexate—psoriasis	4.79e-05	0.000238	CcSEcCtD
Quinine—Nausea—Prednisone—psoriasis	4.74e-05	0.000236	CcSEcCtD
Quinine—Pruritus—Methotrexate—psoriasis	4.72e-05	0.000235	CcSEcCtD
Quinine—KCNH2—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.7e-05	0.00118	CbGpPWpGaD
Quinine—SLCO1A2—Metabolism—CYP2S1—psoriasis	4.7e-05	0.00118	CbGpPWpGaD
Quinine—Diarrhoea—Methotrexate—psoriasis	4.57e-05	0.000227	CcSEcCtD
Quinine—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.57e-05	0.00115	CbGpPWpGaD
Quinine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.57e-05	0.00115	CbGpPWpGaD
Quinine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.5e-05	0.00113	CbGpPWpGaD
Quinine—Dizziness—Methotrexate—psoriasis	4.41e-05	0.00022	CcSEcCtD
Quinine—CYP3A7—Metabolism—NDUFA5—psoriasis	4.34e-05	0.00109	CbGpPWpGaD
Quinine—SLC22A2—Metabolism—NDUFA5—psoriasis	4.33e-05	0.00109	CbGpPWpGaD
Quinine—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	4.28e-05	0.00108	CbGpPWpGaD
Quinine—Vomiting—Methotrexate—psoriasis	4.24e-05	0.000211	CcSEcCtD
Quinine—Rash—Methotrexate—psoriasis	4.21e-05	0.000209	CcSEcCtD
Quinine—Dermatitis—Methotrexate—psoriasis	4.2e-05	0.000209	CcSEcCtD
Quinine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	4.19e-05	0.00106	CbGpPWpGaD
Quinine—Headache—Methotrexate—psoriasis	4.18e-05	0.000208	CcSEcCtD
Quinine—SLC22A1—Metabolism—NDUFA5—psoriasis	4.04e-05	0.00102	CbGpPWpGaD
Quinine—KCNH2—SIDS Susceptibility Pathways—TNF—psoriasis	4.03e-05	0.00101	CbGpPWpGaD
Quinine—SLC22A2—Transmembrane transport of small molecules—CP—psoriasis	4.02e-05	0.00101	CbGpPWpGaD
Quinine—Nausea—Methotrexate—psoriasis	3.96e-05	0.000197	CcSEcCtD
Quinine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.89e-05	0.00098	CbGpPWpGaD
Quinine—SLC22A2—Transmembrane transport of small molecules—CARM1—psoriasis	3.84e-05	0.000967	CbGpPWpGaD
Quinine—SLC22A1—Transmembrane transport of small molecules—CP—psoriasis	3.75e-05	0.000945	CbGpPWpGaD
Quinine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.74e-05	0.000943	CbGpPWpGaD
Quinine—CYP3A7—Metabolism—CYP2S1—psoriasis	3.69e-05	0.000929	CbGpPWpGaD
Quinine—SLC22A2—Metabolism—CYP2S1—psoriasis	3.68e-05	0.000928	CbGpPWpGaD
Quinine—ABCB1—Allograft Rejection—IFNG—psoriasis	3.66e-05	0.000921	CbGpPWpGaD
Quinine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	3.65e-05	0.000919	CbGpPWpGaD
Quinine—SLC22A1—Transmembrane transport of small molecules—CARM1—psoriasis	3.58e-05	0.000902	CbGpPWpGaD
Quinine—SLC22A1—Metabolism—CYP2S1—psoriasis	3.43e-05	0.000865	CbGpPWpGaD
Quinine—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.4e-05	0.000856	CbGpPWpGaD
Quinine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.4e-05	0.000856	CbGpPWpGaD
Quinine—KCNH2—SIDS Susceptibility Pathways—IL6—psoriasis	3.25e-05	0.000819	CbGpPWpGaD
Quinine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.19e-05	0.000803	CbGpPWpGaD
Quinine—CYP2E1—Metabolism—NDUFA5—psoriasis	3.14e-05	0.000791	CbGpPWpGaD
Quinine—CYP3A5—Metabolism—NDUFA5—psoriasis	3.13e-05	0.00079	CbGpPWpGaD
Quinine—CHRM2—SIDS Susceptibility Pathways—CXCL8—psoriasis	3.08e-05	0.000776	CbGpPWpGaD
Quinine—CYP1A1—Metabolism—NDUFA5—psoriasis	2.96e-05	0.000746	CbGpPWpGaD
Quinine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.91e-05	0.000734	CbGpPWpGaD
Quinine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.91e-05	0.000734	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—HCAR2—psoriasis	2.9e-05	0.000731	CbGpPWpGaD
Quinine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	2.89e-05	0.000727	CbGpPWpGaD
Quinine—CHRM2—SIDS Susceptibility Pathways—JUN—psoriasis	2.86e-05	0.000721	CbGpPWpGaD
Quinine—CHRM2—GPCR downstream signaling—CCL20—psoriasis	2.81e-05	0.000708	CbGpPWpGaD
Quinine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.8e-05	0.000705	CbGpPWpGaD
Quinine—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.76e-05	0.000696	CbGpPWpGaD
Quinine—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.76e-05	0.000696	CbGpPWpGaD
Quinine—CHRM2—SIDS Susceptibility Pathways—NFKB1—psoriasis	2.75e-05	0.000694	CbGpPWpGaD
Quinine—CYP2C8—Metabolism—NDUFA5—psoriasis	2.72e-05	0.000684	CbGpPWpGaD
Quinine—CYP2E1—Metabolism—CYP2S1—psoriasis	2.67e-05	0.000673	CbGpPWpGaD
Quinine—CYP3A5—Metabolism—CYP2S1—psoriasis	2.67e-05	0.000672	CbGpPWpGaD
Quinine—CHRM2—Signaling by GPCR—CCL20—psoriasis	2.55e-05	0.000643	CbGpPWpGaD
Quinine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.53e-05	0.000638	CbGpPWpGaD
Quinine—CYP1A1—Metabolism—CYP2S1—psoriasis	2.52e-05	0.000635	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—TAGAP—psoriasis	2.52e-05	0.000634	CbGpPWpGaD
Quinine—CHRM2—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.5e-05	0.00063	CbGpPWpGaD
Quinine—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.46e-05	0.00062	CbGpPWpGaD
Quinine—CYP2C19—Metabolism—NDUFA5—psoriasis	2.42e-05	0.000611	CbGpPWpGaD
Quinine—ABCB1—Allograft Rejection—TNF—psoriasis	2.37e-05	0.000596	CbGpPWpGaD
Quinine—ABCB1—Metabolism—NDUFA5—psoriasis	2.37e-05	0.000596	CbGpPWpGaD
Quinine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.35e-05	0.000593	CbGpPWpGaD
Quinine—CYP2C8—Metabolism—CYP2S1—psoriasis	2.31e-05	0.000582	CbGpPWpGaD
Quinine—SLCO1A2—Metabolism—CARM1—psoriasis	2.29e-05	0.000578	CbGpPWpGaD
Quinine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.26e-05	0.000569	CbGpPWpGaD
Quinine—CYP2D6—Metabolism—NDUFA5—psoriasis	2.23e-05	0.000562	CbGpPWpGaD
Quinine—CHRM2—G alpha (i) signalling events—CXCL8—psoriasis	2.22e-05	0.000559	CbGpPWpGaD
Quinine—CYP2C9—Metabolism—NDUFA5—psoriasis	2.21e-05	0.000557	CbGpPWpGaD
Quinine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.2e-05	0.000554	CbGpPWpGaD
Quinine—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.14e-05	0.00054	CbGpPWpGaD
Quinine—CHRM2—SIDS Susceptibility Pathways—TNF—psoriasis	2.14e-05	0.00054	CbGpPWpGaD
Quinine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.1e-05	0.000528	CbGpPWpGaD
Quinine—CYP2C19—Metabolism—CYP2S1—psoriasis	2.06e-05	0.000519	CbGpPWpGaD
Quinine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.06e-05	0.000519	CbGpPWpGaD
Quinine—ABCB1—Metabolism—CYP2S1—psoriasis	2.01e-05	0.000507	CbGpPWpGaD
Quinine—CYP2D6—Metabolism—CYP2S1—psoriasis	1.9e-05	0.000478	CbGpPWpGaD
Quinine—CYP1A2—Metabolism—NDUFA5—psoriasis	1.89e-05	0.000476	CbGpPWpGaD
Quinine—CYP2C9—Metabolism—CYP2S1—psoriasis	1.88e-05	0.000473	CbGpPWpGaD
Quinine—CYP3A7—Metabolism—CARM1—psoriasis	1.8e-05	0.000454	CbGpPWpGaD
Quinine—SLC22A2—Metabolism—CARM1—psoriasis	1.8e-05	0.000453	CbGpPWpGaD
Quinine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.76e-05	0.000444	CbGpPWpGaD
Quinine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.76e-05	0.000444	CbGpPWpGaD
Quinine—CHRM2—SIDS Susceptibility Pathways—IL6—psoriasis	1.73e-05	0.000436	CbGpPWpGaD
Quinine—SLC22A1—Metabolism—CARM1—psoriasis	1.68e-05	0.000422	CbGpPWpGaD
Quinine—CYP1A2—Metabolism—CYP2S1—psoriasis	1.61e-05	0.000405	CbGpPWpGaD
Quinine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.56e-05	0.000393	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—CCL20—psoriasis	1.51e-05	0.00038	CbGpPWpGaD
Quinine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.5e-05	0.000378	CbGpPWpGaD
Quinine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.46e-05	0.000367	CbGpPWpGaD
Quinine—SLCO1A2—Metabolism—CAT—psoriasis	1.41e-05	0.000356	CbGpPWpGaD
Quinine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.36e-05	0.000343	CbGpPWpGaD
Quinine—CHRM2—GPCR ligand binding—CXCL8—psoriasis	1.34e-05	0.000338	CbGpPWpGaD
Quinine—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.32e-05	0.000333	CbGpPWpGaD
Quinine—CYP2E1—Metabolism—CARM1—psoriasis	1.3e-05	0.000329	CbGpPWpGaD
Quinine—CYP3A5—Metabolism—CARM1—psoriasis	1.3e-05	0.000328	CbGpPWpGaD
Quinine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.24e-05	0.000312	CbGpPWpGaD
Quinine—CYP1A1—Metabolism—CARM1—psoriasis	1.23e-05	0.00031	CbGpPWpGaD
Quinine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.21e-05	0.000305	CbGpPWpGaD
Quinine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.17e-05	0.000294	CbGpPWpGaD
Quinine—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.15e-05	0.00029	CbGpPWpGaD
Quinine—CYP2C8—Metabolism—CARM1—psoriasis	1.13e-05	0.000284	CbGpPWpGaD
Quinine—CYP3A7—Metabolism—CAT—psoriasis	1.11e-05	0.000279	CbGpPWpGaD
Quinine—SLC22A2—Metabolism—CAT—psoriasis	1.11e-05	0.000279	CbGpPWpGaD
Quinine—SLCO1A2—Metabolism—APOE—psoriasis	1.1e-05	0.000276	CbGpPWpGaD
Quinine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.08e-05	0.000272	CbGpPWpGaD
Quinine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.05e-05	0.000266	CbGpPWpGaD
Quinine—SLC22A1—Metabolism—CAT—psoriasis	1.03e-05	0.00026	CbGpPWpGaD
Quinine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.03e-05	0.000259	CbGpPWpGaD
Quinine—CYP2C19—Metabolism—CARM1—psoriasis	1.01e-05	0.000254	CbGpPWpGaD
Quinine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.85e-06	0.000248	CbGpPWpGaD
Quinine—ABCB1—Metabolism—CARM1—psoriasis	9.82e-06	0.000247	CbGpPWpGaD
Quinine—SLCO1A2—Metabolism—PPARG—psoriasis	9.55e-06	0.000241	CbGpPWpGaD
Quinine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.41e-06	0.000237	CbGpPWpGaD
Quinine—CYP2D6—Metabolism—CARM1—psoriasis	9.26e-06	0.000233	CbGpPWpGaD
Quinine—CYP2C9—Metabolism—CARM1—psoriasis	9.18e-06	0.000231	CbGpPWpGaD
Quinine—CYP3A7—Metabolism—APOE—psoriasis	8.61e-06	0.000217	CbGpPWpGaD
Quinine—SLC22A2—Metabolism—APOE—psoriasis	8.59e-06	0.000217	CbGpPWpGaD
Quinine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.58e-06	0.000216	CbGpPWpGaD
Quinine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.42e-06	0.000212	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—SOCS1—psoriasis	8.3e-06	0.000209	CbGpPWpGaD
Quinine—CYP2E1—Metabolism—CAT—psoriasis	8.02e-06	0.000202	CbGpPWpGaD
Quinine—SLC22A1—Metabolism—APOE—psoriasis	8.01e-06	0.000202	CbGpPWpGaD
Quinine—CYP3A5—Metabolism—CAT—psoriasis	8.01e-06	0.000202	CbGpPWpGaD
Quinine—CHRM2—Signaling by GPCR—TYK2—psoriasis	7.92e-06	0.000199	CbGpPWpGaD
Quinine—CYP1A2—Metabolism—CARM1—psoriasis	7.84e-06	0.000198	CbGpPWpGaD
Quinine—CHRM2—GPCR downstream signaling—CXCL8—psoriasis	7.59e-06	0.000191	CbGpPWpGaD
Quinine—CYP1A1—Metabolism—CAT—psoriasis	7.56e-06	0.000191	CbGpPWpGaD
Quinine—CYP3A7—Metabolism—PPARG—psoriasis	7.5e-06	0.000189	CbGpPWpGaD
Quinine—SLC22A2—Metabolism—PPARG—psoriasis	7.49e-06	0.000189	CbGpPWpGaD
Quinine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.33e-06	0.000185	CbGpPWpGaD
Quinine—SLC22A1—Metabolism—PPARG—psoriasis	6.98e-06	0.000176	CbGpPWpGaD
Quinine—CYP2C8—Metabolism—CAT—psoriasis	6.94e-06	0.000175	CbGpPWpGaD
Quinine—CHRM2—Signaling by GPCR—CXCL8—psoriasis	6.89e-06	0.000174	CbGpPWpGaD
Quinine—CYP2E1—Metabolism—APOE—psoriasis	6.23e-06	0.000157	CbGpPWpGaD
Quinine—CYP3A5—Metabolism—APOE—psoriasis	6.22e-06	0.000157	CbGpPWpGaD
Quinine—CYP2C19—Metabolism—CAT—psoriasis	6.19e-06	0.000156	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—LEP—psoriasis	6.13e-06	0.000154	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—APOE—psoriasis	6.13e-06	0.000154	CbGpPWpGaD
Quinine—CYP3A4—Metabolism—CARM1—psoriasis	6.05e-06	0.000152	CbGpPWpGaD
Quinine—ABCB1—Metabolism—CAT—psoriasis	6.04e-06	0.000152	CbGpPWpGaD
Quinine—CYP1A1—Metabolism—APOE—psoriasis	5.88e-06	0.000148	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—NFKBIA—psoriasis	5.71e-06	0.000144	CbGpPWpGaD
Quinine—CYP2D6—Metabolism—CAT—psoriasis	5.69e-06	0.000143	CbGpPWpGaD
Quinine—CYP2C9—Metabolism—CAT—psoriasis	5.64e-06	0.000142	CbGpPWpGaD
Quinine—CYP2E1—Metabolism—PPARG—psoriasis	5.43e-06	0.000137	CbGpPWpGaD
Quinine—CYP3A5—Metabolism—PPARG—psoriasis	5.42e-06	0.000137	CbGpPWpGaD
Quinine—CYP2C8—Metabolism—APOE—psoriasis	5.39e-06	0.000136	CbGpPWpGaD
Quinine—CYP1A1—Metabolism—PPARG—psoriasis	5.12e-06	0.000129	CbGpPWpGaD
Quinine—CYP1A2—Metabolism—CAT—psoriasis	4.82e-06	0.000122	CbGpPWpGaD
Quinine—CYP2C19—Metabolism—APOE—psoriasis	4.81e-06	0.000121	CbGpPWpGaD
Quinine—ABCB1—Metabolism—APOE—psoriasis	4.69e-06	0.000118	CbGpPWpGaD
Quinine—CYP2C8—Metabolism—PPARG—psoriasis	4.69e-06	0.000118	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—TYK2—psoriasis	4.68e-06	0.000118	CbGpPWpGaD
Quinine—CYP2D6—Metabolism—APOE—psoriasis	4.42e-06	0.000111	CbGpPWpGaD
Quinine—CYP2C9—Metabolism—APOE—psoriasis	4.39e-06	0.00011	CbGpPWpGaD
Quinine—CYP2C19—Metabolism—PPARG—psoriasis	4.19e-06	0.000106	CbGpPWpGaD
Quinine—ABCB1—Metabolism—PPARG—psoriasis	4.09e-06	0.000103	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—CXCL8—psoriasis	4.07e-06	0.000103	CbGpPWpGaD
Quinine—CHRM2—Signaling by GPCR—IL6—psoriasis	3.87e-06	9.75e-05	CbGpPWpGaD
Quinine—CYP2D6—Metabolism—PPARG—psoriasis	3.85e-06	9.71e-05	CbGpPWpGaD
Quinine—CYP2C9—Metabolism—PPARG—psoriasis	3.82e-06	9.62e-05	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—JUN—psoriasis	3.78e-06	9.54e-05	CbGpPWpGaD
Quinine—CYP1A2—Metabolism—APOE—psoriasis	3.75e-06	9.44e-05	CbGpPWpGaD
Quinine—CYP3A4—Metabolism—CAT—psoriasis	3.72e-06	9.38e-05	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—NFKB1—psoriasis	3.64e-06	9.18e-05	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—VEGFA—psoriasis	3.31e-06	8.33e-05	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—STAT3—psoriasis	3.27e-06	8.25e-05	CbGpPWpGaD
Quinine—CYP1A2—Metabolism—PPARG—psoriasis	3.26e-06	8.22e-05	CbGpPWpGaD
Quinine—CYP3A4—Metabolism—APOE—psoriasis	2.89e-06	7.29e-05	CbGpPWpGaD
Quinine—CYP3A4—Metabolism—PPARG—psoriasis	2.52e-06	6.35e-05	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—TP53—psoriasis	2.5e-06	6.29e-05	CbGpPWpGaD
Quinine—CHRM2—Signaling Pathways—IL6—psoriasis	2.29e-06	5.76e-05	CbGpPWpGaD
